<![CDATA[FDA Issues Another CRL for Amorphous Dasatinib Receives in CML and ALL]]>
NDA FilingCRLAmorphous DasatinibNegative
AI Analysis
Summary
The FDA issued a Complete Response Letter for amorphous dasatinib in CML and ALL, citing manufacturing observations as the basis for the denial. The regulator did not raise concerns about clinical data, bioequivalence, or stability.
Outcome Details
FDA issued Complete Response Letter citing outstanding manufacturing observations; no concerns raised about clinical data, bioequivalence, or stability
Importance:8/10
Sentiment:
-0.80
regulatoryCRLmanufacturingdasatinibCMLALLoncology
Read the original article
Published by Cancer Network on August 20, 2026 8:30 PM